Interim safety results of a global early access protocol (EAP) of abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) progressing after taxane-based chemotherapy.
暂无分享,去创建一个
F. Saad | C. Sternberg | P. Mainwaring | S. Hotte | D. George | T. Flaig | G. Daugaard | Matthew R. Smith | L. Geczi | A. Molina | A. Londhe | T. McGowan | J. M. Garrido | M. Todd | M. Tay | V. Naini | C. Souza